Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Mk-8408
1. 1613081-64-3
2. Mk-8408
3. Lx752bd95y
4. Carbamic Acid, N,n'-(((6s)-6-(2-cyclopropyl-5-thiazolyl)-1-fluoro-6h-indolo(1,2-c)(1,3)benzoxazine-3,10-diyl)bis(1h-imidazole-5,2-diyl-(2s)-2,1-pyrrolidinediyl((1s)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,c'-dimethyl Ester
5. Methyl N-[(2s)-1-[(2s)-2-[5-[(6s)-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-3-[2-[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]-6h-indolo[1,2-c][1,3]benzoxazin-10-yl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
6. Ruzasvir [usan:inn]
7. Unii-lx752bd95y
8. Ruzasvir [usan]
9. Ruzasvir (usan/inn)
10. Ruzasvir [inn]
11. Ruzasvir [who-dd]
12. Chembl3971095
13. Schembl18268432
14. Db11713
15. J3.601.978f
16. D11217
17. Q27283234
18. Dimethyl ((2s,2's)-((2s,2's)-(((s)-6-(2-cyclopropylthiazol-5-yl)-1-fluoro-6h-benzo[5,6][1,3]oxazino[3,4-a]indole-3,10-diyl)bis(1h-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-1,2-diyl))dicarbamate
| Molecular Weight | 947.1 g/mol |
|---|---|
| Molecular Formula | C49H55FN10O7S |
| XLogP3 | 6.4 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 14 |
| Exact Mass | 946.39599347 g/mol |
| Monoisotopic Mass | 946.39599347 g/mol |
| Topological Polar Surface Area | 230 Ų |
| Heavy Atom Count | 68 |
| Formal Charge | 0 |
| Complexity | 1840 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Ruzasvir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ruzasvir, including repackagers and relabelers. The FDA regulates Ruzasvir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ruzasvir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ruzasvir supplier is an individual or a company that provides Ruzasvir active pharmaceutical ingredient (API) or Ruzasvir finished formulations upon request. The Ruzasvir suppliers may include Ruzasvir API manufacturers, exporters, distributors and traders.
Ruzasvir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ruzasvir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ruzasvir GMP manufacturer or Ruzasvir GMP API supplier for your needs.
A Ruzasvir CoA (Certificate of Analysis) is a formal document that attests to Ruzasvir's compliance with Ruzasvir specifications and serves as a tool for batch-level quality control.
Ruzasvir CoA mostly includes findings from lab analyses of a specific batch. For each Ruzasvir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ruzasvir may be tested according to a variety of international standards, such as European Pharmacopoeia (Ruzasvir EP), Ruzasvir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ruzasvir USP).
LOOKING FOR A SUPPLIER?
